Pattern of Lipid Profile in Adult HIV Seropositives  in Nnewi, Nigeria by Ezeugwunne, Ifeoma Priscilla et al.
Food Science and Quality Management                                                                                                                                             www.iiste.org 
ISSN 2224-6088 (Paper)  ISSN 2225-0557 (Online) 
Vol.29, 2014 
 
35 
Pattern of Lipid Profile in Adult HIV Seropositives  
in Nnewi, Nigeria 
 
Ifeoma Priscilla Ezeugwunne 
1*
, Charles Chinedu Onyenekwe 
2
, Joseph Ebere Ahaneku 
2
 
Martins Ifeanyichukwu 
3
, Gladys Ahaneku 
4
, Samuel Chukwuemeka Meludu 
1
 
Rebecca Chinyere Chukwuanukwu
3
 Wuraola Serah Nnaemeka
1
, Charles  Dike 
1
,  Christian Ejike  Onah 
5
 
1.Department of Human Biochemistry; College of Health Sciences, Nnamdi Azikiwe University, Nnewi, Nigeria 
2. Department of Chemical Pathology; College of Health Sciences, Nnamdi Azikiwe University, Nnewi, Nigeria 
3 .Department of Immunology, College of Health Sciences, Nnamdi Azikiwe University, Nnewi, Nigeria 
4. Department of Medicine, College of Health Sciences, Nnamdi Azikiwe University, Nnewi, Nigeria 
5. Department of Chemical Pathology; Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria 
* Corresponding author, E-mail: goodnessifeoma007@yahoo.com 
 
 The research is financed by Tertiary Educational Trust Fund (TETFUND), Nigeria. 
 
Abstract 
To determine the lipid profile level in adult HIV seropositive participants. Blood samples collected from the 300 
randomly recruited participants were used for HIV screening, CD4
+
 T cell count, total Cholesterol, Low Density 
Lipoprotein (LDL), High Density Lipoprotein (HDL) and Triglyceride. Standard Laboratory methods were used 
for the analysis. The results showed that the mean serum total Cholesterol, LDL, HDL, Triglyceride and CD4
+
 T 
cell levels were significantly different amongst the groups studied. The mean serum total Cholesterol, LDL, 
HDL and Triglyceride levels were significantly lower in symptomatic HIV participants on antiretroviral therapy 
(ART) compared with those not on ART (P<0.05) but no significant difference was observed between the groups 
in CD4
+
 T cell level (p>0.05). The mean serum total Cholesterol, LDL, HDL, Triglyceride and CD4
+
 T cell 
levels were significantly lower in  symptomatic HIV participants on ART compared with control group (in each 
case). Also, the mean serum HDL and CD4
+
 T cell levels were significantly lower while the mean LDL was 
significantly higher in symptomatic HIV participants not on ART compared with  control subjects (P<0.05) but 
the values seen in total Cholesterol and Triglycerides were the same in both groups (P>0.05). Hypolipidaemia 
was seen in HIV positive participants. 
Keywords: HIV, lipid profile, participants. 
 
1. Introduction 
Human Immunodeficiency virus (HIV) is transmitted as single stranded enveloped RNA virus and upon entry 
into the host, is converted into double stranded proviral DNA by reverse transcriptase enzyme of the virus. The 
proviral DNA is then inserted into the host cell genomic DNA, the virus becomes active and replicates within 
cells (Vandegraaff & Engelman, 2007). 
During the asymptomatic state, as the name suggests, the individual is free from major symptoms, although there 
may be swollen glands (WHO, 2006). But, during the stage of symptomatic stage, there are emergence of 
opportunistic infection and cancers. At this point, the body immune system has been compromised and severely 
damaged by HIV and could lead to a disease called Acquired Immunodeficiency syndrome (AIDS) (WHO, 
2006).  
AIDS has been observed to have effect on lipid profile in HIV seropositive individuals (Grinspoon & Carr, 2005, 
Oduola et al, 2009). HIV infection has been found to impact on the adipocytes, disabling it from storing most 
lipids (Broxmeyer, 2004). Even, before the advance of ART, low levels of total Cholesterol, HDL and LDL have 
been reported in HIV infection (Akiibinu et al, 2008,Madhav et al, 2009). Hence, this study is intended to 
evaluate the pattern of lipid profile, in adult HIV seropositive individuals. 
 
2 Materials and Methods 
2.1 Subjects 
The study was conducted in Nnamdi Azikiwe University (NAUTH), Nnewi in Anambra state, South East 
Nigeria. Three hundred subjects were randomly recruited from the voluntary and counseling unit (VCT) of 
NAUTH for this study. Using the World Health Organization (WHO, 2006), staging for HIV as a guide and 
questionnaire, the participants were grouped, comprising of 100 symptomatic HIV subjects on ART, 100 
symptomatic HIV subjects not on ART and 100 HIV seronegative control subjects. These participants had no 
history of any disease. Ethical approval was sort and obtained from the NAUTH ethics committee and informed 
consent was obtained from the participants. 
2.2 Sample collection 
Six milliliter (6 ml) of fasting blood samples were collected from all the participants in this study. 2ml of blood 
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samples were collected into EDTA sample tubes for HIV screening and CD4+ T cell count. The remaining 4 ml 
of blood sample were collected into plain tube and allowed to clot, centrifuged, the serum separated and 
analyzed for total Cholesterol, LDL, HDL and Triglyceride.  
2.3 Quality control measures 
Quality control sera were run along test in each batch of analysis these were compared with the reference values 
of the control sera. Standard deviation and coefficient of variation were calculated on them. 
2.4 Methods of assaying 
2.4.1 Determination of Antibodies to HIV-1 and HIV-2 in Human plasma. 
Procedure 
Two different methods were used, namely, Abbott determine TM HIV -1 and HIV-2 kit, which is an in-vitro 
visually read immunoassay (Abbott Japan Co.Ltd.Tokyo, Japan) and HIV-1 and 2 STAT-PAK Assay kit, which 
is an Immunochromatographic test for the quantitative detection of antibodies to HIV-1 and HIV-2 in Human 
plasma (CHEMBIO Diagnostic system, Inc, New York, USA). For the Abbott determine TM HIV -1 and HIV-2 
kit, the procedure described by the manufacturer was used for the analysis. Briefly, 50 µl of participant serum 
samples separated from the corresponding whole blood samples in EDTA were applied to the appropriately 
labeled sample pad. After 15 minutes but not more than 60 minutes of sample application, the result was read. 
This method has inherent quality control that validates the results. For the Immunochromatographic method for 
HIV -1 and HIV-2, the procedure described by the manufacturer was used for the analysis. In brief, 5 ml of 
participant’s plasma was dispensed into the sample well in the appropriately labeled sample pad. Three drops of 
the buffer supplied by the manufacturer was added into the appropriately labeled sample pad. The results of the 
test were read at 10 minutes after the addition of the running buffer. This method has inherent quality control and 
validates the results.  
2.4.2 Determination of CD4
+
T cells counts by CyFlows SL-Green 
Procedure 
200 ml EDTA whole blood was collected into PARTEC test tubes (Rohren tube). Then 20 µl of CD4
+
 T 
antibody was added into the tube. The contents was mixed and incubated in the dark for15 minutes at room 
temperature. 800 ml of CD4 buffer was added into the mixture and mixed gently. Then the Partec tube was 
plugged on the Cyflow counter and the CD4
+
 T cells were displayed as peaks and interpreted as figures. 
2.4.3 Quantitative determination of serum Cholesterol  
Procedure 
The procedure was as described by the manufacturer (Randox Laboratories, UK).  10 µl of standards, specimens 
and controls were dispensed into appropriately labeled standards, specimens and controls tubes respectively. 1 
ml of cholesterol reagent containing (phenol- 6 mmol/L, pipes buffer- 50 mmol/L, 4-amino antipyrine- 0.3 
mmol/L, cholesterol oxidase- 100 U/L, cholesterol estrase- 150 U/L and peroxidase 800 U/L) was added to each 
of the tube.  The reagent blank was prepared similarly with the use of 10 µl of distilled water. These were 
incubated for 10 minutes at room temperation and absorbance measured at 546 nm against reagent blank and the 
concentration of serum cholesterol was calculated. 
 2.4.4 Quantitative determination of serum Triglyceride  
Procedure 
The procedure was as described by the manufacturer (Randox Laboratories, UK). 10 µl of standards, specimens 
and controls were dispensed into appropriately labeled standards, specimens and controls tubes respectively. 
1000 µl of enzyme reagent was added to each of the tube.  The reagent blank was prepared similarly with the use 
of 10 µl of distilled water. These were incubated for 10 minutes at room temperation and their absorbances 
measured at 546 nm against reagent blank  and the concentration of serum cholesterol was calculated. 
2.4.5 Quantitative determination of serum High Density Lipoprotein Cholesterol (HDL-C) 
Procedure 
The procedure was as described by the manufacturer (Randox Laboratories, UK). 500 µl of serum, control were 
dispensed into appropriately labeled specimens and controls tubes respectively. 1000 µl of HDL precipitant 
(phosphotungstic acid- 0.55 mmol/L and magnesium ions- 25 mmol/L) was added to each of the tube. This was 
incubated for 10 minutes at room temperature and then centrifuged at 4000 rpm for 10 minutes. 100 µl of the 
clear supernatant was used to determine cholesterol content by cholesterol assay mothod. The HDL content was 
then calculated. 
2.4.6 Quantitative determination of serum Low Density Lipoprotein Cholesterol (LDL-C) 
The formula by Kaplan and colleagues (8) was used to calculate the LDL-C level. Initially, the total cholesterol, 
triglyceride and HDL-C levels of each sample were determined and the LDL level was calculated using this 
formula: LDL-C = Total cholesterol – (HDL-C + 1/5 x triglyceride). The formula hinges on the postulation that 
VLDL-C is present in a concentration equal to one fifth of the triglyceride concentration. This postulation is 
valid for triglyceride concentrations less than 4.56 mmol/L. 
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2.5 Data analysis 
The result of the analysis was statistically analyzed. Students’t-test and one way analysis of variance (ANOVA) 
were used to compare means. The analyses were performed with the use of Statistical Package for Social 
Sciences (SPSS) statistical software package, version 16.0. P <0.05 is considered statistically significant. 
 
3. Results 
The result of the analysis of variance showed that the mean serum total Cholesterol, LDL, HDL, Triglyceride 
(mmol/l) levels and CD4+ T cell counts were significant different amongst the groups at P < 0.05 (F = 316.27; 
273.30; 134.00, 423.00 and 216.22) respectively. 
Between group comparison showed that the mean serum total Cholesterol, LDL, HDL,  Triglyceride and CD4
+
 
T-Cell levels were significantly lower in symptomatic HIV infected subjects not on ART compared with 
asymptomatic HIV infected subjects at p<0.05, in each case. 
Again, between group comparison showed that the mean serum total Cholesterol LDL, HDL Triglyceride and 
CD4
+
 T-Cell levels were significantly lower in symptomatic HIV infected subjects not on ART compared HIV 
seronegative control subjects at p<0.05 respectively.  
Also, between group comparison showed that the mean serum total Cholesterol, HDL and CD4
+
 T-Cell levels 
were significantly lower in asymptomatic HIV infected subjects compared with HIV seronegative control 
subjects at p<0.05 respectively. But a significantly higher mean serum levels of LDL and Triglyceride  were seen 
in asymptomatic HIV infected subjects compared with HIV seronegative control subjects at p<0.05 respectively 
(See table 1). 
Table 1: Comparison of mean ± SD serum levels of Lipid profile in symptomatic HIV infected subjects on ART 
(A),  symptomatic HIV infected subjects not on ART (B) and control group (C). 
Group Chol (mmol/L) LDL (mmol/L) HDL (mmol/L) TG (mmol/L) 
CD4 
 (/mL) 
A(n=100) 3.51±0.22 1.75±0.06 0.91±0.06 0.79±0.04 374.78 ± 121.59 
B(n=100) 4.27±0.15 2.76±0.07 1.20±0.03 1.35±0.04 437.20 ±129.75 
C(n=100) 4.62±0.24 2.34±0.13 1.37±0.06 1.44±0.05 940.64 ± 148.85 
F(p)-value 124.50 (.000) 482.27 (.000) 305.96 (.000) 1300 (.000) 
126.37 
  (.000) 
A v B <0.05 <0.05 <0.05 <0.05 >0.05 
A v C <0.05 <0.05 >0.05 <0.05 <0.05 
B v C >0.05 <0.05 <0.05 >0.05 <0.05 
Key: F (p) value = mean ± SD of parameter compared among groups A, B and C (using ANOVA). 
A V B p value = mean ± SD of parameter compared between group A and B (using t-test). 
B V C p value = mean ± SD of parameter compared between group A and C (using t-test). 
B V C p value = mean ± SD of parameter compared between group A and D (using t-test). 
 
4. Discussion 
In this study, there were significantly lower levels in serum total cholesterol, LDL, HDL and TG in symptomatic 
HIV participants with and without Antiretroviral therapy. The finding conformed to the finding by Grunfeld et al 
(1992) that observed lower levels in serum total cholesterol, LDL, HDL and TG in HIV positive participants.  
Adewole et al (2010) observed lower levels in LDL and HDL, reaching a dyslipidemic level in HIV positive 
group when compared with control. The reduced serum lipid profile in symptomatic HIV positives may be 
suggesting hypolipidaemia in these subjects. Hypolipidaemia is an abnormal lipid distribution in tissues; the 
supply of cholesterol may be compromised leading to nerve damaged or impairment as well as steroidal 
hormonal imbalance in the individual. 
There were also significantly lower levels of serum total cholesterol, HDL and TG in symptomatic HIV positive 
individuals on ART compared with control in the present research. These reductions in levels could be the result 
of slower rate in lipid production due ro HIV infectionand enhanced lipid catabolic rate associated with HIV 
infection (Akiibinu et al, 2008, Madhav et al, 2009). Therefore, the significant fall in total cholesterol, HDL and 
TG status of HIV infected individuals may be a determinant in ascertaining factors that predisposes severity of 
disease in them. 
Some researchers have reported that the presence of abnormal lipid in HIV infected individuals might be due to 
the effects of viral infection, acute-phase reactant and circulating cytokines (Christeff et al, 2002). Therefore, the 
significant fall in total cholesterol, HDL and TG status of HIV infected individuals may be a determinant in 
ascertaining factors that predisposes severity of disease in HIV infected individuals. 
Another significant finding in this study was that participants with HIV infection had more depleted CD4
+
T cells 
in symptomatic HIV not on ART. Ifeanyichukwu et al (2011) was able to link rate of CD4
+ 
T cell depletion with 
HIV disease progression. While Mark et al (2005) reported that the reduced CD4
+
T cell counts in HIV 
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seropositives may be attributed to cell death caused by the HIV infection.  
 
5 Conclusion 
In this study, we conclude that the serum levels of total Cholesterol, Low density lipoprotein and the blood level 
of CD4+ T cell counts were significantly reduced in adult symptomatic HIV positive subjects with or without 
ART. The reduced serum lipid profile suggests hypolipidaemia as well as dyslipidemia in these subjects. Hence, 
the study suggests that the prediction of severity and monitoring of disease could be done by evaluating the 
CD4+ T cell counts and lipid profile in HIV infected individuals. Identification of these biomarkers in these 
individuals will aid in their early detection, treatment and management.  
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